VENUS MEDTECH-B (02500) has announced that on December 29, 2025, the seller, Venus Medtech (Hong Kong) Limited, entered into a share transfer agreement with the buyer, Broncus China Holding Corporation. Under the agreement, the seller has agreed to sell, and the buyer has agreed to purchase, the sale shares for a consideration of $15 million. The shares represent approximately 1.05% of the total issued shares of the invested company, Valgen Holding Corporation, on the date of this announcement, calculated on a fully diluted and converted basis. The invested company is an exempted company incorporated and existing under the laws of the Cayman Islands. It is primarily engaged in providing systematic solutions for conditions such as mitral regurgitation and tricuspid regurgitation. To prioritize the reallocation of resources for developing its core products and supporting its long-term business growth, the Company is continuously streamlining its investment portfolio and focusing on its main business operations. As a minority financial investor in the invested company, the disposal presents an appropriate opportunity for the Group to realize its investment: by divesting non-core business investments, the Group will be able to strengthen its cash flow, improve its working capital position, enhance overall financial flexibility, and facilitate the reallocation of resources to its core businesses. The Board believes that prudent capital management, including this disposal, is beneficial for ensuring the sustainable development of the Group and enhancing shareholder returns.